Research Article
BibTex RIS Cite

Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?

Year 2022, Volume: 13 Issue: 4, 456 - 462, 30.12.2022
https://doi.org/10.18663/tjcl.1034014

Abstract

Amaç: Yüksek serum gamma- glutamiltransferaz (GGT) seviyelerinin koroner arter hastalığı olan bireylerde ve akut koroner sendromda kötü klinik sonuçlarla ilişkili olduğu gösterilmiştir. Koroner kollateral gelişimi dokuyu hipoksiye karşı koruyan çok önemli bir mekanizmadır. Bu çalışmada GGT seviyeleri ile koroner kollateral dolaşım (KKD) arasındaki ilişki araştırıldı.
Araçlar ve yöntem: Çalışmaya koroner anjiyografi (KAG) uygulanan ve en az bir major epikardiyal koroner arterinde %95 ve üzerinde darlık saptanan 216 hasta (176 erkek, ort yaş 62,8±9,6) geriye dönük olarak dahil edildi. KKD Rentrop skorlama sistemi kullanılarak derecelendirildi. Az gelişmiş KKD grubuna rentrop 0-1 kollateral dolaşımı olan, iyi gelişmiş KKD grubuna rentrop 2-3 kollateral dolaşımı olan hastalar alındı.
Bulgular: Seksen (55 erkek, ort yaş 62,6±9,2 yıl) hasta az gelişmiş KKD grubunu; 136 (92 erkek, ort yaş 62,9±9,8 yıl) hasta ise iyi gelişmiş KKD grubunu oluşturdu. İki grup yaş, cinsiyet, koroner arter hastalığı risk faktörleri, ilaç kullanımı ve sigara içiciliği açısından benzer bulundu. Serum GGT seviyeleri ile koroner kollateral gelişimi açısından iki grup arasında anlamlı fark saptanmadı. Gensini skoruyla belirlenen koroner arter hastalığı yaygınlığı (45 ± 46 vs. 91 ± 35, p < 0.001) ve tutulan damar sayısı iyi koroner kollateral gelişimiyle ilişkili bulundu. Çok değişkenli lojistik regresyon analizinde tutulan damar sayısının (OR = 0.98, p < 0.001) koroner kollateral gelişiminin bağımsız risk faktörü olduğu saptandı.
Sonuç: Tutulan damar sayısı ve gensini skoru ile koroner kollateral gelişimi arasında belirgin ilişki saptanırken, serum GGT düzeyleri ile koroner kollateral gelişimi arasında ilişki saptanmadı.

Supporting Institution

yok

References

  • Sincer I, Mansiroglu AK, Erdal E, Cosgun M, Aktas G, Gunes Y. Could platelet distribution width predict coronary collateral development in stable coronary artery disease? North Clin Istanb. 2020;7(2):112-117.
  • Lee DH, Pei CZ, Song JY, et al. Identification of serum biomarkers for premature ovarian failure. Biochim Biophys Acta Proteins Proteom. 2019;1867(3):219-226.
  • Han K, Lu Q, Zhu WJ, Wang TZ, Du Y, Bai L. Correlations of degree of coronary artery stenosis with blood lipid, CRP, Hcy, GGT, SCD36 and fibrinogen levels in elderly patients with coronary heart disease. Eur Rev Med Pharmacol Sci. 2019;23(21):9582-9589.
  • Zhou JP, Tong XY, Zhu LP, et al. Plasma Omentin-1 Level as a Predictor of Good Coronary Collateral Circulation. J Atheroscler Thromb. 2017;24(9):940-948.
  • Ballı M, Çetin M, Taşolar H, et al. The relationship between serum thyroid hormone levels, subclinical hypothyroidism, and coronary collateral circulation in patients with stable coronary artery disease. Turk Kardiyol Dern Ars. 2016;44(2):130-136.
  • Gök M, Kundi H, Kızıltunç E, Topcuoglu C, Ornek E. The relationship between ischaemia-modified albumin and good coronary collateral circulation. Kardiol Pol. 2018;76(2):370-375.
  • Akdag S, Akyol A, Asker M, Ozturk F, Gumrukcuoglu HA. The relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with non-ST segment elevation myocardial infarction. Postepy Kardiol Interwencyjnej. 2016;12(3):224-230.
  • Gok M, Kundi H, Kiziltunc E, Topcuoglu C, Ornek E. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-48.
  • Türker Duyuler P, Duyuler S, Gök M, Kundi H, Topçuoğlu C, Güray Ü. Pleiotrophin levels are associated with improved coronary collateral circulation. Coron Artery Dis. 2018;29(1):68-73.
  • Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38(6):535-539.
  • Huang Y, Luo J, Liu X, et al. Gamma-Glutamyltransferase and Risk of Acute Coronary Syndrome in Young Chinese Patients: A Case-Control Study. Dis Markers. 2018;2018:2429160.
  • Rentrop KP, Thornton JC, Feit F, Van Buskirk M. Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. Am J Cardiol. 1988;61(10):677-684.
  • Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.
  • You XD, Jin JL, Zhang H, et al. Lipoprotein(a) as a marker for predicting coronary collateral circulation in patients with acute myocardial infarction. Per Med. 2020;17(1):67-78.
  • Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010;13(1):36-41.
  • Li X, Bu S, Dong B, et al. The predictive values of GGT and Hcy in the risk stratifications and prognoses of NSTE-ACS patients. Am J Transl Res. 2021;13(8):9269-9277.
  • Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(1):127-133.
  • Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4(24):481.
  • Demirtaş K, Yayla Ç, Sade LE, et al. Platelet Membrane Γ-Glutamyl Transferase-Specific Activity and the Clinical Course of Acute Coronary Syndrome.
  • Onat A, Can G, Örnek E, Çiçek G, Ayhan E, Doğan Y. Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012;20(4):842-848
  • Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-2362.
  • Ndrepepa G, Braun S, Schunkert H, Laugwitz KL, Kastrati A. Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. Clin Chim Acta. 2016;452:155-160.
  • Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol. 2012;57(5):1083-1089.
  • Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis. 2015;238(2):356-364.

Could serum gamma glutamyltransferase level be a predictor of coronary collateral circulation in patients with stable coronary artery patients?

Year 2022, Volume: 13 Issue: 4, 456 - 462, 30.12.2022
https://doi.org/10.18663/tjcl.1034014

Abstract

References

  • Sincer I, Mansiroglu AK, Erdal E, Cosgun M, Aktas G, Gunes Y. Could platelet distribution width predict coronary collateral development in stable coronary artery disease? North Clin Istanb. 2020;7(2):112-117.
  • Lee DH, Pei CZ, Song JY, et al. Identification of serum biomarkers for premature ovarian failure. Biochim Biophys Acta Proteins Proteom. 2019;1867(3):219-226.
  • Han K, Lu Q, Zhu WJ, Wang TZ, Du Y, Bai L. Correlations of degree of coronary artery stenosis with blood lipid, CRP, Hcy, GGT, SCD36 and fibrinogen levels in elderly patients with coronary heart disease. Eur Rev Med Pharmacol Sci. 2019;23(21):9582-9589.
  • Zhou JP, Tong XY, Zhu LP, et al. Plasma Omentin-1 Level as a Predictor of Good Coronary Collateral Circulation. J Atheroscler Thromb. 2017;24(9):940-948.
  • Ballı M, Çetin M, Taşolar H, et al. The relationship between serum thyroid hormone levels, subclinical hypothyroidism, and coronary collateral circulation in patients with stable coronary artery disease. Turk Kardiyol Dern Ars. 2016;44(2):130-136.
  • Gök M, Kundi H, Kızıltunç E, Topcuoglu C, Ornek E. The relationship between ischaemia-modified albumin and good coronary collateral circulation. Kardiol Pol. 2018;76(2):370-375.
  • Akdag S, Akyol A, Asker M, Ozturk F, Gumrukcuoglu HA. The relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with non-ST segment elevation myocardial infarction. Postepy Kardiol Interwencyjnej. 2016;12(3):224-230.
  • Gok M, Kundi H, Kiziltunc E, Topcuoglu C, Ornek E. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-48.
  • Türker Duyuler P, Duyuler S, Gök M, Kundi H, Topçuoğlu C, Güray Ü. Pleiotrophin levels are associated with improved coronary collateral circulation. Coron Artery Dis. 2018;29(1):68-73.
  • Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38(6):535-539.
  • Huang Y, Luo J, Liu X, et al. Gamma-Glutamyltransferase and Risk of Acute Coronary Syndrome in Young Chinese Patients: A Case-Control Study. Dis Markers. 2018;2018:2429160.
  • Rentrop KP, Thornton JC, Feit F, Van Buskirk M. Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. Am J Cardiol. 1988;61(10):677-684.
  • Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.
  • You XD, Jin JL, Zhang H, et al. Lipoprotein(a) as a marker for predicting coronary collateral circulation in patients with acute myocardial infarction. Per Med. 2020;17(1):67-78.
  • Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010;13(1):36-41.
  • Li X, Bu S, Dong B, et al. The predictive values of GGT and Hcy in the risk stratifications and prognoses of NSTE-ACS patients. Am J Transl Res. 2021;13(8):9269-9277.
  • Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(1):127-133.
  • Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4(24):481.
  • Demirtaş K, Yayla Ç, Sade LE, et al. Platelet Membrane Γ-Glutamyl Transferase-Specific Activity and the Clinical Course of Acute Coronary Syndrome.
  • Onat A, Can G, Örnek E, Çiçek G, Ayhan E, Doğan Y. Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012;20(4):842-848
  • Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-2362.
  • Ndrepepa G, Braun S, Schunkert H, Laugwitz KL, Kastrati A. Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. Clin Chim Acta. 2016;452:155-160.
  • Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol. 2012;57(5):1083-1089.
  • Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis. 2015;238(2):356-364.
There are 24 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Orıgınal Artıcle
Authors

Sebahat Tekeli Şengül 0000-0002-6010-1319

Betül Banu Karasu 0000-0001-7084-0038

Erol Kalender 0000-0003-0479-0866

Özcan Özeke 0000-0002-4770-8159

Publication Date December 30, 2022
Published in Issue Year 2022 Volume: 13 Issue: 4

Cite

APA Tekeli Şengül, S., Karasu, B. B., Kalender, E., Özeke, Ö. (2022). Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?. Turkish Journal of Clinics and Laboratory, 13(4), 456-462. https://doi.org/10.18663/tjcl.1034014
AMA Tekeli Şengül S, Karasu BB, Kalender E, Özeke Ö. Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?. TJCL. December 2022;13(4):456-462. doi:10.18663/tjcl.1034014
Chicago Tekeli Şengül, Sebahat, Betül Banu Karasu, Erol Kalender, and Özcan Özeke. “Serum Gamma Glutamiltransferaz Seviyeleri Stabil Koroner Arter hastalarında Koroner Kollateral gelişiminin Belirleyicisi Olabilir Mi?”. Turkish Journal of Clinics and Laboratory 13, no. 4 (December 2022): 456-62. https://doi.org/10.18663/tjcl.1034014.
EndNote Tekeli Şengül S, Karasu BB, Kalender E, Özeke Ö (December 1, 2022) Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?. Turkish Journal of Clinics and Laboratory 13 4 456–462.
IEEE S. Tekeli Şengül, B. B. Karasu, E. Kalender, and Ö. Özeke, “Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?”, TJCL, vol. 13, no. 4, pp. 456–462, 2022, doi: 10.18663/tjcl.1034014.
ISNAD Tekeli Şengül, Sebahat et al. “Serum Gamma Glutamiltransferaz Seviyeleri Stabil Koroner Arter hastalarında Koroner Kollateral gelişiminin Belirleyicisi Olabilir Mi?”. Turkish Journal of Clinics and Laboratory 13/4 (December 2022), 456-462. https://doi.org/10.18663/tjcl.1034014.
JAMA Tekeli Şengül S, Karasu BB, Kalender E, Özeke Ö. Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?. TJCL. 2022;13:456–462.
MLA Tekeli Şengül, Sebahat et al. “Serum Gamma Glutamiltransferaz Seviyeleri Stabil Koroner Arter hastalarında Koroner Kollateral gelişiminin Belirleyicisi Olabilir Mi?”. Turkish Journal of Clinics and Laboratory, vol. 13, no. 4, 2022, pp. 456-62, doi:10.18663/tjcl.1034014.
Vancouver Tekeli Şengül S, Karasu BB, Kalender E, Özeke Ö. Serum gamma glutamiltransferaz seviyeleri stabil koroner arter hastalarında koroner kollateral gelişiminin belirleyicisi olabilir mi?. TJCL. 2022;13(4):456-62.


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.